SAR405: Selective ATP-Competitive Vps34 Inhibitor for Precision Autophagy Inhibition

Executive Summary: SAR405 is a potent and selective class III PI3K (Vps34) inhibitor that blocks autophagy by disrupting the kinase's ATP binding site, with a dissociation constant (Kd) of 1.5 nM and an IC₅₀ of 1 nM against recombinant human Vps34 under standard in vitro conditions (APExBIO SAR405 product data). It does not inhibit class I and II PI3Ks or mTOR at concentrations up to 10 μM, ensuring high selectivity. SAR405 impairs late endosome-lysosome function and cathepsin D maturation, resulting in autophagosome formation blockade in multiple human cell lines (Park et al., 2023). Its use has elucidated the Vps34 kinase signaling pathway and advanced translational research in cancer and neurodegenerative disease models. As a tool compound, SAR405 enables precise dissection of autophagy mechanisms and vesicle trafficking.

Biological Rationale

Autophagy is a conserved catabolic pathway responsible for cellular homeostasis, especially during metabolic or nutrient stress (Park et al., 2023). Vps34, or class III phosphoinositide 3-kinase (PI3K), is the only PI3K isoform essential for autophagosome nucleation and vesicle trafficking. Genetic or pharmacological disruption of Vps34 impairs autophagy induction, lysosome function, and cathepsin maturation. The recent paradigm shift in AMPK-ULK1 signaling has highlighted the need for precise tools to dissect the upstream and downstream effects of autophagy inhibition (Park et al., 2023). SAR405 addresses this gap by enabling selective, ATP-competitive inhibition of Vps34, thus allowing researchers to parse the role of Vps34-dependent autophagy in cancer, neurodegeneration, and homeostatic stress. APExBIO provides SAR405 (SKU A8883) as a research-grade compound for these applications.

Mechanism of Action of SAR405

SAR405 is an ATP-competitive inhibitor that binds the ATP-binding cleft of Vps34 with sub-nanomolar affinity (Kd = 1.5 nM, IC₅₀ = 1 nM) under standard kinase assay conditions (Tris buffer pH 7.4, 25°C). This interaction is highly selective, with no inhibition of class I/II PI3Ks or mTOR up to 10 μM (APExBIO SAR405 technical data). By blocking Vps34 activity, SAR405 disrupts the generation of phosphatidylinositol 3-phosphate (PI3P), thereby impairing autophagosome nucleation and vesicle trafficking. In cell-based models such as GFP-LC3 HeLa and H1299 lines, SAR405 treatment leads to the accumulation of swollen late endosome-lysosome compartments and defective cathepsin D maturation, phenocopying genetic Vps34 knockout (Park et al., 2023).

Evidence & Benchmarks

• SAR405 inhibits recombinant human Vps34 kinase activity with a Kd of 1.5 nM and IC₅₀ of 1 nM (APExBIO product data, link).
• No detectable inhibition of class I/II PI3Ks or mTOR was observed up to 10 μM (APExBIO, link).
• SAR405 blocks autophagosome formation in GFP-LC3 HeLa and H1299 cells, measured by loss of LC3 puncta and accumulation of late endosome-lysosome vesicles (Park et al., 2023, DOI).
• SAR405 impairs cathepsin D maturation, indicating a defect in late endosome-lysosome function (Park et al., 2023, DOI).
• Combining SAR405 with mTOR inhibitors (e.g., everolimus) yields synergistic autophagy inhibition in cell-based assays (APExBIO, link).

For further scenario-driven guidance on SAR405's nanomolar potency and workflow optimization, see the practical review at Vatalis, which this article updates by integrating recent AMPK-ULK1 signaling insights and new selectivity data.

This review extends the mechanistic clarity provided in GTP-Binding Protein Fragment G-Alpha by scrutinizing SAR405's role in lysosome dysfunction and autophagosome blockade in light of the latest Nature Communications findings.

For detailed experimental design strategies using SAR405 in translational models, see the overview at BKM120.net; the current article clarifies selectivity and workflow integration boundaries not previously specified.

Common Pitfalls or Misconceptions

• SAR405 is not effective against class I or class II PI3Ks, nor mTOR, above 10 μM; off-target effects are minimal at recommended concentrations.
• SAR405 should not be used as a general PI3K pathway inhibitor; its action is specific to Vps34.
• Autophagy inhibition by SAR405 may be incomplete if used in models with compensatory non-canonical pathways.
• Long-term SAR405 solution storage (> days at 4°C or RT) leads to loss of activity; always prepare fresh working stocks below -20°C.
• SAR405 is not water-soluble; improper solvent use (e.g., aqueous buffers without DMSO) will cause precipitation and loss of activity.

Applications, Limits & Misconceptions

SAR405 is validated for dissecting Vps34 kinase signaling in autophagy inhibition, vesicle trafficking modulation, and lysosome function impairment. It is used in cancer research, neurodegenerative disease models, and for probing AMPK-ULK1 pathway regulation. Its selectivity enables precise mapping of class III PI3K-dependent processes, providing a strategic advantage over less selective inhibitors (Park et al., 2023). However, SAR405 does not inhibit upstream kinases (e.g., mTOR, class I/II PI3Ks) and cannot block autophagy induced by Vps34-independent mechanisms. It is not a substitute for genetic knockout in chronic studies, as compensatory effects may arise. Use of SAR405 in non-dividing or terminally differentiated cells requires validation, as Vps34 dependency may differ by context.

Workflow Integration & Parameters

Preparation: SAR405 is soluble in DMSO at >10 mM and in ethanol with ultrasonic assistance; it is insoluble in water. Prepare stock solutions in DMSO below -20°C. Avoid repeated freeze-thaw cycles and do not store working solutions for more than one week at 4°C (APExBIO).

Assay Design: Use SAR405 at concentrations of 1–500 nM for in vitro kinase or cell-based assays. Always include vehicle (DMSO) controls. Assess autophagy blockade using LC3 puncta, p62/SQSTM1 accumulation, or cathepsin D maturation in appropriate cell lines. For synergy studies, combine SAR405 with mTOR inhibitors (e.g., everolimus, rapamycin) and measure autophagic flux (Park et al., 2023).

Storage & Handling: Store dry compound or concentrated DMSO stocks at -20°C. Protect from light and moisture. Do not use aqueous buffers for primary dissolution.

Conclusion & Outlook

SAR405 is a best-in-class, selective ATP-competitive Vps34 inhibitor, uniquely suited for mechanistic and translational studies of autophagy, vesicle trafficking, and lysosome biology. Its nanomolar potency and high isoform selectivity, validated by APExBIO, enable researchers to dissect Vps34-dependent pathways with high confidence. By integrating recent discoveries in AMPK-ULK1 signaling (Park et al., 2023), SAR405 advances the precision of autophagy research and offers a platform for therapeutic innovation in cancer and neurodegeneration. For detailed product specifications and ordering, see the SAR405 product page at APExBIO.